Connect
MJA
MJA

Clinical trials of unapproved medicines in Australia

Jonathon Rankin, Jenny Mason, Neil Kottege and Natasha Y Andersson
Med J Aust 2006; 185 (6): 342-343.
Published online: 18 September 2006

To the Editor: The Experimental Drugs Section (EDS) of the Drug Safety and Evaluation Branch of the Therapeutic Goods Administration (TGA) administers the clinical trial notification (CTN) and clinical trial exemption (CTX) arrangements for unapproved medicines used in clinical trials. These arrangements provide an avenue of “exemption”, whereby medicines that have not been approved for marketing in Australia are able to be supplied to patients within the context of a clinical trial approved by a human research ethics committee working under the guidelines of the Australian Health Ethics Committee (a subcommittee of the National Health and Medical Research Council). Although these arrangements cover only clinical trials in which unapproved medicines are used, a substantial number of such trials are carried out in Australia each year. (Clinical trials using unapproved medical devices that also use the CTN/CTX arrangements are administered by the TGA’s Office of Blood, Devices and Tissues and are not included in these statistics.)

  • Jonathon Rankin
  • Jenny Mason
  • Neil Kottege
  • Natasha Y Andersson

  • Experimental Drugs Section, Drug Safety and Evaluation Branch, Therapeutic Goods Administration, Australian Government Department of Health and Ageing, Canberra, ACT.

Correspondence: jon.rankin@health.gov.au

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.